German drugmaker Bayer said on Thursday it will cut about 800 jobs from its U.S. operations to cut costs following its acquisition of rival Schering AG.
Bayer will eliminate 600 positions, primarily in research, and cut an additional 200 U.S.-based workers over time in an overall reorganization.
The company said that after one-time costs of about $350 million, it will be able to reduce overall research and development expenses by more than $210 million per year by the end of 2008.
Source: Reuters
So remind me again about how Big Pharma is a research oriented business and not just a huge sales and marketing outfit.
Coincidentally, Insider was looking at the excellent blog In the Pipeline and noticed that it's author, the chemist Derek Lowe, is job hunting.
1 comment:
Derek is passing along information on behalf of the rest of us (chemistry, biology, you name it) as well, so if you know of anyone who is hiring please let him know.
Post a Comment